Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25575447 | 0.93 | TSHR (0.36) | LMNASMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL26521168 | 0.93 | SMN1; SMN2 (0.36) | LMNASMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL19696373 | 0.91 | GSK3A (0.34) | LMNASMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL18557382 | 0.90 | AKT1 (0.34) | LMNASMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL24048990 | 0.89 | LMNA (0.33) | LMNASMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL22353284 | 0.88 | LMNA (0.33) | LMNASMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL24533285 | 0.88 | AKT1 (0.33) | LMNASMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL19057844 | 0.87 | LMNA (0.32) | LMNASMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL23261511 | 0.87 | LMNA (0.32) | LMNASMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL20865050 | 0.87 | LMNA (0.32) | LMNASMN1; SMN2HPGDHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355654-A1 | RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11534453-B2 | RNAi therapy for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220211868-A1 | NANOPARTICLES COMPRISING NON-CLASSICAL MHC AND USES THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2022-07-07 | — | — | US | disclosed |
| US-11338024-B2 | Methods and compositions for sustained immunotherapy | UTI LIMITED PARTNERSHIP (CA) | 2022-05-24 | — | — | US | disclosed |
| US-20210052624-A1 | RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10806750-B2 | RNAi therapy for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190022123-A1 | RNAi Therapy for Hepatitis B Virus Infection | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-01-24 | — | — | US | disclosed |
| US-20180127481-A1 | RECOMBINANT pMHC CLASS II MOLECULES | UTI LIMITED PARTNERSHIP (CA) | 2018-05-10 | — | — | US | disclosed |
| US-20170056472-A1 | Peptide-Based In Vivo siRNA Delivery System | Arrowhead Pharmaceuticals, Inc. | 2017-03-02 | — | — | US | disclosed |
| US-20170035796-A1 | RNAi Therapy for Hepatitis B Virus Infection | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806750-B2 | RNAi therapy for hepatitis B virus infection | HAVCR2, NR1H4, SRRT | LMNA 2737/4885SMN1; SMN2 4639/4885HPGD 3824/4885 |
| US-20170056472-A1 | Peptide-Based In Vivo siRNA Delivery System | VIP, RNASE1, APLNR | LMNA 811/4885SMN1; SMN2 2653/4885HPGD 4529/4885 |
| US-20180127481-A1 | RECOMBINANT pMHC CLASS II MOLECULES | MICA, TAP2, CD74 | LMNA 3273/4885SMN1; SMN2 3371/4885HPGD 3657/4885 |
| US-20210052624-A1 | RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION | HAVCR2, NR1H4, SRRT | LMNA 2737/4885SMN1; SMN2 4639/4885HPGD 3824/4885 |
| US-11534453-B2 | RNAi therapy for hepatitis B virus infection | HAVCR2, NR1H4, SRRT | LMNA 2737/4885SMN1; SMN2 4639/4885HPGD 3824/4885 |
| US-20190022123-A1 | RNAi Therapy for Hepatitis B Virus Infection | HAVCR2, NR1H4, SRRT | LMNA 2737/4885SMN1; SMN2 4639/4885HPGD 3824/4885 |
| US-20170035796-A1 | RNAi Therapy for Hepatitis B Virus Infection | HAVCR2, NR1H4, SRRT | LMNA 2737/4885SMN1; SMN2 4639/4885HPGD 3824/4885 |
| US-11338024-B2 | Methods and compositions for sustained immunotherapy | CD47, TFRC, ICOS | LMNA 3403/4885SMN1; SMN2 337/4885HPGD 2334/4885 |
| US-20230355654-A1 | RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION | HAVCR2, NR1H4, SRRT | LMNA 2737/4885SMN1; SMN2 4639/4885HPGD 3824/4885 |
| US-20220211868-A1 | NANOPARTICLES COMPRISING NON-CLASSICAL MHC AND USES THEREOF | MICA, CD74, HLA-C | LMNA 2484/4885SMN1; SMN2 2635/4885HPGD 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.